识别与年龄相关的黄斑退化症的系统生物标志物和潜在的药物标
Shizhen Lei1, Mang Hu1, Zhongtao Wei2
1Department of Ophthalmology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Frontiers in aging neuroscience
|February 16, 2024
概括
某些与衰老相关的蛋白质 (SRPs) 的高血水平,包括C3b,CTNNB1,CCL1和CCL3L1,与与年龄相关的黄斑变性 (AMD) 的风险增加有关. 这突出了系统性炎症.
科学领域:
- 遗传学 是一个遗传学.
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
背景情况:
- 与年龄相关的黄斑变性 (AMD) 是与衰老和细胞衰老相关的视力丧失的主要原因.
- 细胞衰老涉及衰老细胞的积累,导致与年龄相关的疾病.
- 与衰老相关的蛋白质 (SRPs) 的血水平可能作为AMD风险的生物标志物.
研究的目的:
- 研究与衰老相关蛋白质 (SRPs) 的血水平与患上与年龄相关的黄斑变性 (AMD) 的风险之间的关联.
- 使用遗传数据探索特定的SRP和AMD之间的潜在因果关系.
主要方法:
- 采用了双样本的孟德尔随机化 (MR) 分析.
- 逆变量加权 (IVW) 方法是主要的分析方法.
- 利用来自大型队列 (FinnGen和英国生物银行) 的110个SRP和AMD风险的全基因组关联研究 (GWAS) 数据.
主要成果:
- 在四种SRP (C3b,CTNNB1,CCL1和CCL3L1) 的血水平和AMD风险增加 (IVW-P < 0.00045) 之间发现了因果关系.
- 在另外10个SRP中确定了潜在的因果关系.
- 没有检测到显著的异质性或质性,这支持了研究结果的稳定性.
结论:
- 血中C3b,CTNNB1,CCL1和CCL3L1的升高水平与患AMD的风险更高有关.
- 这些发现强调了系统性炎症在AMD发病过程中的作用.
- 这些结果为开发AMD新型预防和治疗策略提供了基础.
更多相关视频
10:14Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
3.1K
06:16Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
Published on: July 28, 2023
2.5K
相关概念视频
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...